Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut health meets diet: a new angle on managing multiple sclerosis

NCT ID NCT07789171

Disease control Sponsor: Hacettepe University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This trial tests whether adding a synbiotic supplement to a Mediterranean diet can improve quality of life and reduce disability in people with relapsing-remitting multiple sclerosis. Participants follow the diet for 12 weeks and take either a synbiotic or a placebo pill daily. Researchers measure changes in quality of life, disability scores, body measurements, and mood.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A synbiotic supplement (probiotic plus prebiotic) taken alongside a Mediterranean diet plan
What this could lead to
If it works, this could point toward a dietary approach that helps manage MS symptoms and improve daily life.
What could go wrong
The trial is small and early, so results may not apply broadly. Supplements can cause digestive discomfort, and the diet may be hard to follow.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

38 people

The number who actually took part.

Started

Mar 2020

Finished

Nov 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 64 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Being aged 19-64 years * Having an EDSS score of 6.5 or below, * Being clinically diagnosed with RRMS and being under the care of the relevant outpatient clinic, * Having had no attacks in the last month, * Not receiving immunosuppressive drug therapy (Cyclophosphamide, Methotrexate, Azathioprine, Mitoxantrone, Mycophenolate Mofetil) * Not being deficient in vitamin D * Being a female diagnosed at least one year ago (to ensure a homogeneous gender distribution in the group and because the incidence of MS is higher in females) Exclusion Criteria: * Individuals who have used probiotics/synbiotics or antibiotics within the last two weeks prior to participating in the study, either on a doctor's advice or of their own accord, and who will be required to use probiotics/synbiotics or antibiotics during the study period. * Individuals with enteric inflammation, advanced liver or kidney disease, * Individuals diagnosed by a physician with diabetes, hyperlipidemia, gout, chronic renal failure, or liver disease requiring special medical nutrition therapy, * Pregnant or lactating women, * Individuals with a body mass index of 30 kg/m2 or above, * Individuals who have participated in another clinical trial within the last month, * Individuals who have previously reported sensitivity to probiotic/synbiotic treatment, * Individuals whose standard medical treatment or medication dosage is changed or planned to change during the study period, * Individuals who cannot ensure continuity in research follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis (MS) - relapsing-remitting are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis (MS) - relapsing-remitting

Contacts and locations

Locations

  • Hacettepe University

    Ankara, Ankara, 06230, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.